ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

MHB048C

A development code. Also written as “MHB048C for Injection”.

Its studies are mostly in Prostatic Neoplasms, led by Minghui Pharmaceutical.

Furthest: phase 2, since Sep 17, 20251 company-led study, 1 open or runningNext primary completion: Oct 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Minghui Pharmaceutical11 open or runningphase 2since Sep 17, 2025Sep 17, 2025Oct 2029phase 2 · NCT07192120

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 17, 2025First study: phase 2 study in mCRPC (Metastatic Castration-resistant Prostate Cancer)First studyNCT07192120 · 200 planned · China

Ahead

  1. Oct 2029Primary completion: phase 2 study in mCRPC (Metastatic Castration-resistant Prostate Cancer)NCT07192120

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07192120mCRPC (Metastatic Castration-resistant Prostate Cancer) · China2RecruitingOct 2029200

How it is read

Names in the registry

  • “MHB048C for Injection”, 1 entry

Codes read as this program: MHB048C.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.